]>
IRCT20190127042516N1 IRCT 2019-02-13 Islamic Azad University Effect of Losartan discontinuation on treatment of anemia in hemodialysis patients The effect of discontinuation of angiotensin-II receptor blocker on therapeutic effect of synthetic erythropoietin on anemia modification in hemodialysis patients 2019-02-09 anticipated 28 Complete https://irct.ir/trial/37205 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: This research is a clinical trial and pre- and post-intervention method. The duration of the intervention is three months. The values ​​of the relevant variable (hemoglobin level) before the treatment intervention (control group) will compared with the values ​​after the discontinuation of the drug (test group). Immediately prior to discontinuing and replacing losartan, the venous blood sample is taken as a control group for testing.The losartan will discontinued and the blood pressure will controlled with the oral antihypertensive medication other than ACE-I or ARB categories. After three months of treatment intervention, blood samples are taken again as the test group. Blood samples of 5cc from the intravenous line of vascular access are obtained immediately before hemodialysis. Blood hemoglobin level (gr / dl) is measured with Cell Counter Mindry BC 3000Plus machine. N/A Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease. Intervention 1: Intervention group: Discontinuation of Losartan. Intervention 2: Control group: Hemodialysis patients on Losartan for at least 3 months. Yes - There is a plan to make this available What will be shared: Demographic information and the results of the main outcome after unidentifiable patients can be shared. When: Six months after the publication of the results and with an official request To whom: All nephrologists working in research institutes and universities Conditions: Use of data is subject to observance of intellectual property rights of the researcher Where to obtain: khazaeem@yahoo.com How to obtain: Maximum one month after receipt of the request. Comments:
public Mahmood Reza Khazaei
No. 1/34, 20th Rahnemaee Ave., Rahnemaee St., Ahmadabad
Mashhad Iran (Islamic Republic of) 91856667773 +98 51 3840 1279 khazaeem@mshdiau.ac.ir Islamic Azad University scientific Mahmood Reza Khazaei
No. 1/34, 20th Rahnemaee Ave., Rahnemaee St., Ahmadabad
Mashhad Iran (Islamic Republic of) 91856667773 +98 51 3840 1279 khazaeem@mshdiau.ac.ir Islamic Azad University Iran (Islamic Republic of) All hypertensive patients with ESRD on regular hemodialysis consist of 3 4-hours session per week. Use of Losartan at least the last three months no limit no limit Both Dosage alteration for rHuEPO, ferrous sulfate and Carnitine supplementation. Serious infection leading hospitalization Obvious bleeding Transfusion Surgery CRP>10 mg/L Serum Ferritin <100 ng/ml Any alteration in hemodialysis dosage/time I13.11 Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease Treatment - Drugs Treatment - Drugs Intervention group: Discontinuation of Losartan Control group: Hemodialysis patients on Losartan for at least 3 months Hemoglobin increment. Timepoint: Before intervention and 3 months after discontinuation of Losartan. Method of measurement: Cell Counter Mindry BC 3000Plus machine. Personal cost Approved 2018-09-05 ٍEthics committee in bio-medicine research - Mashhad branch Sarab Ave., Azadi st. Mashhad Razavi Khorasan Iran (Islamic Republic of)